A positive ACE2 immunostaining was detectable in 3542 (28.0%) of the 12,644 analysable tumours, including 2029 (16.0%) with weak, 708 (5.6%) with moderate and 805 (6.4%) with strong immunostaining. This evidence concerns the gene ACE2 and neoplasm.